Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Totaligent, Inc. entered into a definitive agreement dated April 10, 2026 with Ivan Klarich. The agreement is tied to integrating Aetherium Medical’s assets into a joint venture with GloMed Solutions.
The Aetherium Medical platform is described as an infrastructure layer for AI-enabled biologic therapies, using cold-chain logistics, turnkey commercialization, and clinical-partner enablement across Asia-Pacific medical-tourism channels. The foundational operating business behind the platform has generated approximately $10 million in annual revenue and has been profitable for more than 15 years, supported by a proprietary network of more than 20 key opinion leaders and specialty clinics. The agreement states that Don Heath receives no compensation, equity, or other consideration under this agreement, with any Heath arrangements governed by a separate definitive agreement.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026